Literature DB >> 12773069

Valproic acid-induced neutropenia.

Kimi S Vesta1, Patrick J Medina.   

Abstract

OBJECTIVE: To report a case of severe neutropenia caused by valproic acid (VPA). CASE
SUMMARY: A 56-year-old white woman with an infectious brain abscess causing tonic-clonic seizure activity was treated with VPA. She developed severe neutropenia after 2 days of VPA therapy. The absolute neutrophil count reached a nadir of 47 cells/mm(3) during VPA use and returned to normal upon its discontinuation. DISCUSSION: VPA is considered to be a well-tolerated antiepileptic drug. While neutropenia has been reported, it has been mild and transient. This patient developed severe neutropenia during effective treatment with VPA, making her significantly susceptible to infection. The Naranjo probability scale indicates VPA as the probable cause of neutropenia in this case.
CONCLUSIONS: This report of severe neutropenia caused by VPA emphasizes the importance of monitoring complete blood cell counts during therapy with this agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773069     DOI: 10.1345/aph.1C381

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  Valproate induced isolated neutropenia.

Authors:  Utkarsh Kohli; Sheffali Gulati
Journal:  Indian J Pediatr       Date:  2006-09       Impact factor: 1.967

2.  Response to clozapine in a clinically identifiable subtype of schizophrenia.

Authors:  Nancy J Butcher; Wai Lun Alan Fung; Laura Fitzpatrick; Alina Guna; Danielle M Andrade; Anthony E Lang; Eva W C Chow; Anne S Bassett
Journal:  Br J Psychiatry       Date:  2015-03-05       Impact factor: 9.319

Review 3.  Anticonvulsant drugs and hematological disease.

Authors:  A Verrotti; A Scaparrotta; S Grosso; F Chiarelli; G Coppola
Journal:  Neurol Sci       Date:  2014-03-12       Impact factor: 3.307

4.  Neutropenia and Leukopenia After Cross Taper From Quetiapine to Divalproex for the Treatment of Borderline Personality Disorder.

Authors:  Caroline Richmond; Stephanie Coveart
Journal:  Fed Pract       Date:  2022-04-11

Review 5.  Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.

Authors:  Rosanne W Meijboom; Koen P Grootens
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

6.  Novel use of granulocyte colony stimulating factor as an adjunct for treatment of schizoaffective disorder complicated by sodium valproate induced agranulocytosis.

Authors:  S Subbarayan; S Thomas; M George
Journal:  Indian J Psychiatry       Date:  2012-07       Impact factor: 1.759

7.  A case with neutropenia related with the use of various atypical antipsychotics.

Authors:  Myung Ho Lim; Jong-Il Park; Tae Won Park
Journal:  Psychiatry Investig       Date:  2013-12-16       Impact factor: 2.505

8.  Severe Pancytopenia Induced by Valproic Acid.

Authors:  Andrew Wahba; Emmalee Bergez
Journal:  Cureus       Date:  2020-10-30

9.  Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder; a case report.

Authors:  Hiroki Matsuura; Sohei Kimoto; Izumi Harada; Satoshi Naemura; Kazuhiko Yamamuro; Toshifumi Kishimoto
Journal:  BMC Psychiatry       Date:  2016-05-26       Impact factor: 3.630

10.  Dextromethorphan Protect the Valproic Acid Induced Downregulation of Neutrophils in Patients with Bipolar Disorder.

Authors:  Ru-Band Lu; Yun-Hsuan Chang; Sheng-Yu Lee; Tzu-Yun Wang; Shu-Li Cheng; Po-See Chen; Yen-Kuang Yang; Jau-Shyong Hong; Shiou-Lan Chen
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-02-29       Impact factor: 2.582

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.